The drug has been launched under the brand names Glempa, Glempa –L and Glempa-M
Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognised SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).
These medications are designed to improve glycemic control in adults with T2DM while reducing cardiovascular outcomes in T2DM patients with CV risk.
Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, ” Glenmark has a strong legacy of introducing innovative and accessible treatments for Cardiometabolic care in India. The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.”
